HOUSTON--(BUSINESS WIRE)--CTMC, a joint venture between MD Anderson Cancer Center and Resilience, celebrates one year since its founding to accelerate life-saving cell therapies reaching patients. During its first year, CTMC has partnered with MD Anderson investigators and biotech companies to bring several novel cell therapies through Investigational New Drug (IND)-enabling studies and U.S. Food and Drug Administration (FDA) interactions to initiate clinical development.
“Our team and partners have made incredible strides in the past year to advance co-developed therapeutics,” said Jason Bock, CEO, CTMC. “This has been enabled by a collaborative framework in which each stakeholder is aligned to accelerate development of transformational cell therapies to impact patients.”
Milestones for CTMC in its first year include:
- In July 2022, CTMC and Obsidian Therapeutics announced FDA clearance of the IND application for Obsidian’s novel tumor-infiltrating lymphocyte (TIL) therapy, OBX-115.
- In September 2022, CTMC partnered with Ori Biotech to accelerate development of new cell therapies using Ori’s cell therapy manufacturing platform.
- In December 2022, CTMC and Invectys announced FDA clearance of the IND application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.
- In March 2023, CTMC unveiled four new cleanrooms totaling 2,700 square feet to expand its manufacturing space dedicated solely to cell therapies. These flexible, ballroom-style cleanrooms are designed to adapt easily to any process or product.
- In May 2023, CTMC was awarded $9.1M in the newly created Cancer Prevention & Research Institute of Texas (CPRIT) Texas New Technologies Company grant.
- Finalized implementation of digital systems for research and development, quality management, regulatory filings, inventory management, environmental monitoring, and equipment calibration.
CTMC’s unique model accelerates the development of innovative cell therapies for patients with cancer. The team of 80+ employees is based at its 60,000-square-foot, industrial-grade cGMP manufacturing facility in the Texas Medical Center. Just steps away from MD Anderson Cancer Center, CTMC drives life-saving cell therapies from the pre-clinical stage through regulatory filing into clinical development.
Representatives from CTMC will be present at BIO in Boston from June 5-8.
About CTMC
CTMC – a joint venture between MD Anderson Cancer Center and Resilience – was created to accelerate the development and manufacturing of impactful cell therapies for patients with cancer. CTMC is uniquely positioned within the Texas Medical Center to provide therapies that begin and end with the patient. By leveraging the strengths of MD Anderson and Resilience we start clinical trials faster and provide a clear path to robust commercialization. Learn more at www.ctmc.com.
